Shortcut Navigation:

2015 Grant Recipients

Initiator Awards

Celine Emmanuelle Riera, PhD

Celine Emmanuelle Riera, PhD

The University of California, Berkeley, CA
Identification of Sensory Neural Circuits Controlling Metabolic Disorders
Grant #1-15-INI-12 

In order to adapt quickly to changes in environmental conditions and perception of internal senses (such as digestion, temperature, hunger, pain and blood pressure), mammals rely on a part of the brain called the hypothalamus to integrate a variety of signals into appropriate responses and meet energy demand. However, it is not well understood whether neurons involved in sensory perception have the ability to translate sensory information into metabolic responses through communication with the hypothalamus and other brain regions. By focusing on the critical senses of pain and smell, which play important roles in the perception of harmful conditions and nutrient availability, this project will identify components of the metabolic response that become disrupted in type 2 diabetes. 

Through better understanding of these sensory systems, and how they impact metabolic activity, new therapies to treat type 2 diabetes may be identified.

Stephanie Stanford, PhD

Stephanie Stanford, PhD

La Jolla Institute for Allergy and Immunology, La Jolla, CA
PTPN22: Model Gene to Unravel the Interaction between Genetics and Environment in Type 1 Diabetes
Grant #1-15-INI-13 

A mutation in a gene called PTPN22 is one of the strongest known genetic risk factors for type 1 diabetes (T1D). Viral infections are important risk factors for development of T1D, and the PTPN22 gene may play a critical role in defense against viruses. This project will study whether the mutated PTPN22 gene predisposes individuals to T1D by decreasing the response to viral infections. The results from this study will elucidate the mechanism by which a genetic T1D risk factor combines with an environmental trigger to confer disease susceptibility. Importantly, if correct, this model suggests that protection from and/or aggressive treatment of viral infections could prevent T1D in people with this genetic risk factor, and will pave the way to preventative treatment strategies for individuals at high risk of developing T1D.

Accelerator - Early Investigator Awards

Thomas Delong, PhD

Thomas Delong, PhD

The University of Colorado Denver, Aurora, CO
The Role of Hybrid Insulin Peptides in the Development of Type 1 Diabetes
Grant #1-15-ACE-14

Type 1 diabetes (T1D) is an autoimmune disease that is mediated by the immune system's own T cells. Normally, T cells fight infection by mounting a response to foreign bodies, called antigens, when they are detected in the circulation. While the immune system has mechanisms to prevent T cells from recognizing self-antigens, in T1D those mechanisms fail and T cells inappropriately attack the body’s own insulin-producing beta cells. In order to prevent or reverse the development of T1D it is therefore critical to understand why and how T cells are misguided. This project describes a modification to self-antigens that are recognized by T cells that trigger diabetes in a major animal model for T1D. The researchers hypothesize that the same modification is relevant in the development of human T1D. They will test this hypothesis using T cells that were isolated from the remaining islet tissue of deceased human T1D patients. Additionally, the researchers have identified a potential mechanism that leads to these antigen modifications. They will study the mechanism and test whether the formation of modified antigens can be chemically inhibited, thereby blocking destruction of insulin-producing beta cells and preventing type 1 diabetes.

Zhen Gu, PhD

Zhen Gu, PhD

North Carolina State University, Raleigh, NC and University of North Carolina at Chapel Hill
Bio-Inspired Synthetic Pathway for Closed-Loop Delivery of Insulin and Glucagon  
Grant #1-15-ACE-21 

A therapeutic system capable of automatically regulating insulin delivery in proportion to blood glucose levels is highly desirable for people with type 1 and advanced type 2 diabetes. Several synthetic glucose-responsive formulations for self-regulated delivery of insulin have been developed. However, there are numerous remaining challenges to crafting a biocompatible system that would be easy to administer, provide a sufficiently fast insulin response, and prevent hypoglycemia. Inspired by the natural insulin vesicles in pancreatic beta cells, this project will develop artificial "synthetic insulin vesicles". The hypothesis is that the materials will be able to regulate release of insulin at high blood glucose levels and inhibit its release within the normal glucose range. To prevent potential hypoglycemia, the project includes design of "synthetic glucagon vesicles" to counteract unexpected large releases of insulin. If successful, these systems can fundamentally change how type 1 diabetes is managed and reduce the burden of monitoring and treatment.

Marie-France Hivert, MD

Marie-France Hivert, MD

Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA
Understanding Pathways of Fetal Metabolic Programming to Stop the Transgenerational Risk of Diabetes
Grant #1-15-ACE-26

Exposure to maternal hyperglycemia in the womb is associated with significantly higher lifetime risk of type 2 diabetes (T2D). The exact mechanisms explaining this phenomenon are still unknown. This project will apply recent technological advances to examine differences in how epigenetic regulation (one of the mechanisms that controls gene expression) is linked to in utero exposure to diabetes. By following mother-child pairs throughout pregnancy and childhood, the study is expected to identify new information about which epigenetic adaptations across the human genome are implicated in linking maternal blood glucose to the offspring’s future T2D risk. Revealing new information about how T2D is triggered in these children could aid development of early life prevention measures to reduce rates of diabetes in future generations.

Accelerator - New to Diabetes Award

Mayland Chang, PhD

Mayland Chang, PhD

University of Notre Dame, South Bend, IN
A Strategy to Accelerate Diabetic Wound Repair
Grant #1-15-ACN-06 

A serious complication of diabetes is the inability of wounds to heal, which contributed to 73,000 lower-limb amputations in the United States in 2010. Currently, no therapeutic agents for the treatment of diabetic wounds are approved and there is a paucity of research to understand why diabetic wounds are difficult to heal. Preliminary work has identified enzymes called “matrix metalloproteinases” (MMPs) that seem to influence wound healing in diabetic mice. In addition, a drug has been identified that selectively blocks the detrimental MMP, is not toxic to mice, and is poised for development as a topical therapy for diabetic wound healing. This project proposes to validate the beneficial and detrimental roles of MMPs in human samples and to understand how MMP inhibitor drugs may improve diabetic wound healing. The combination of studies applying selective MMP inhibitors and using samples from people with diabetes is expected to lead to a new treatment for this serious complication of diabetes.

2014 Grant Recipients

Initiator Awards

Michael Dennis, PhD

Michael Dennis, PhD

The Pennsylvania State University, Hershey, PA
Hyperglycemia-induced translational control of gene expression in the retina
Grant #1-14-INI-04

Nearly all people with type 1 diabetes, and the majority with type 2, experience some degree of retinopathy in their lifetime. Unfortunately, treatments that fully address the molecular pathogenesis of this complication are presently lacking. The overall goal of this research project is to identify mechanisms that regulate hyperglycemia-induced expression of factors that control blood vessel growth and proliferation in the retina. This research strategy represents a new and fundamentally different approach to investigate the molecular players responsible for retinal neurovascular complications, and will allow validation of novel targets for intervention at the level of gene expression. This study may ultimately lead to the development of innovative, non-destructive therapies that address the cause of diabetic retinopathy.

Stephen Parker, PhD

Stephen Parker, PhD

University of Michigan, Ann Arbor, MI
Deconstructing type 2 diabetes using genome-wide high-density multi-tissue 'omics' profiling
Grant #1-14-INI-07

Susceptibility to type 2 diabetes is partly encoded in the genetic code, or DNA. Exactly how changes in DNA lead to diabetes susceptibility and progression, however, currently remains unclear. Recent studies suggest that most disease-associated genetic variations reside not within the coding regions of genes, but instead outside the genes—in regions generally referred to as regulatory elements. These elements control when, where, and how much a gene is turned on. This project is geared to identify these hidden regulatory elements and link them to the genes they control. Such information can lead to quantitative disease surveillance over time, and will help identify the next generation of type 2 diabetes drug targets. Integration of these results with a personal DNA code can help guide "custom" treatment strategies based on the specific combination of risk changes an individual may have.

Accelerator - Early Investigator Awards

Kathleen Page, MD

Kathleen Page, MD

University of Southern California, Los Angeles, CA
Neural mechanisms in maternal-fetal programming for obesity and diabetes
Grant #1-14-ACE-36

Exposure to environmental stressors early in life, such as prenatal exposure to diabetes, appears to contribute to the development of type 2 diabetes later in life.  Animal studies suggest that fetal exposure to maternal diabetes may cause changes in brain pathways that help control body weight and blood sugar. The goal of our research is to use cutting edge neuroimaging techniques to characterize brain pathways involved in body weight and blood sugar control in children who were either exposed or unexposed to diabetes in utero. This project will identify early life markers in brain appetite pathways that may contribute to the development of obesity and type 2 diabetes. These newly identified markers can then be used to develop interventions to prevent obesity and diabetes in high-risk children. These studies could help find new ways to prevent diabetes in those at highest risk and to develop new ways to treat patients with diabetes.

Joshua Thaler, MD, PhD

Joshua Thaler, MD, PhD

University of Washington, Seattle, WA
Modulating glial-neuronal interactions to treat obesity and diabetes
Grant #1-14-ACE-51

Therapies for diabetes have largely involved insulin: providing insulin, making the body produce more of its own insulin, or making the body more sensitive to the effects of insulin. All of these approaches work directly on the insulin target tissues (liver, muscle, fat) and are critical parts of diabetes treatment. However, because the brain also helps control blood sugar, medications that target brain systems as opposed to insulin target tissues could be a useful new approach to managing diabetes. We have found that the brain becomes impaired in obesity in a way that may affect body weight and blood sugar balance. This project explores the possibility that glial cells (the brain's damage response cells) in the hypothalamus area of the brain play an important part in the process of becoming obese and developing diabetes. We are using a wide variety of techniques to study and manipulate glial cells in order to determine the extent of their contribution to weight and blood sugar regulation and whether they can be engineered to help reverse obesity and diabetes.

Accelerator - New to Diabetes Award

Wolfgang Peti, PhD

Wolfgang Peti, PhD

Brown University, Providence, RI
Novel, innovative insights into insulin signaling and regulation using NMR spectroscopy
Grant #1-14-ACN-31 (New to Diabetes Research)

The prevalence of diabetes in the US is now at epidemic levels. In order to develop new drugs that not only improve treatment, but eventually provide a cure, requires a full understanding of the signaling pathways in the body that drive this disease. The aim of this project is to apply state-of-the-art molecular approaches to study the protein enzymes that regulate insulin signaling and glycogen metabolism. This project uses nuclear magnetic resonance (NMR) spectroscopy, the high-resolution cousin of magnetic resonance imaging (MRI), to study these proteins. This cutting edge technique will provide insight into how these enzymes function—down to the atomic level. More importantly, it will enable the investigation of how the intrinsic functions of these enzymes can be used to design novel, more potent drugs to fight diabetes.

Powered by Convio
nonprofit software